

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/17CP		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam A. Peyman			
				FILING DATE March 27, 2002		GROUP	

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>F</i>	A.L	WO 01/26591	04/2001	International	A61F	9/O08	N/A
<i>F</i>	A.M	WO 01/39764	06/2001	International	A61K	31/O0	N/A
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>Pub</i>	A.R	Bressler et al., Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration With Verteporfin-TAP Report 2, Archives in Ophthalmology, Vol. 119, 198-207, February 2001.
<i>Dub.</i>	A.S	Bressler, Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin-TAP Report 1, Archives in Ophthalmology, Vol. 117, 1329-1345, October 1999.
<i>F</i>	A.T	Ciulla et al., Presumed Macular Choroidal Watershed Vascular Filling, Choroidal Neovascularization, and Systemic Vascular Disease in Patients With Age-related Macular Degeneration, American Journal of Ophthalmology, Vol. 126, No. 1, 153-155, July 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/17CP

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam A. PeymanFILING DATE
March 27, 2002

GROUP

(37 CFR 1.98(b))

(Use several sheets if necessary)




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	B.R	Ciulla et al., <u>Color Doppler Imaging Discloses Reduced Ocular Blood Flow Velocities in Nonexudative Age-related Macular Degeneration</u> , American Journal of Ophthalmology, Vol. 128, No. 1, 75-80, July 1999.
	B.S	Friedman et al., <u>Ocular Blood Flow Velocity in Age-related Macular Degeneration</u> , Ophthalmology, Vol. 102, No. 4, 640-646, April 1995.
	B.T	Friedman, <u>A Hemodynamic Model of the Pathogenesis of Age-related Macular Degeneration</u> , American Journal of Ophthalmology, Editorial, Vol. 124, No. 5, 677-682, November 1997.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/17CP

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam A. PeymanFILING DATE
March 27, 2002

GROUP

(37 CFR 1.98(b))

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)



	C.R	Glaser et al., <u>Feeder Vessel Treatment for Age-related Macular Degeneration (AMD) with Classic Choroidal Neovascularization (CNV)</u> , Association for Research in Vision and Ophthalmology Annual Convention, Ft. Lauderdale, Florida, Abstract #1243-B556, May 2001.
	C.S	Glaser and Murphy, <u>High-Speed ICG Choroidal Angiography</u> , Review of Ophthalmology, 110-112, September 2000.
	C.T	Grunwald et al., <u>Foveolar Choroidal Blood Flow in Age-Related Macular Degeneration</u> , Investigative Ophthalmology & Visual Science, Vol. 39, No. 2, 385-390, February 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/17CP		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary)				APPLICANT Gholam A. Peyman			
				FILING DATE March 27, 2002		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
A	D.R	Johnson et al., <u>A Potential Role for Immune Complex Pathogenesis in Drusen Formation</u> , Experimental Eye Research, Vol. 70, No. 4, 441-449, April 2000.					
A	D.S	Klingel et al., <u>Rheopheresis: Rheologic, Functional, and Structural Aspects</u> , Therapeutic Apheresis, Vol. 4, No. 5, 348-356, 2000.					
A	D.T	Lip et al., <u>Age-related Macular Degeneration is Associated with Increased Vascular Endothelial Growth Factor, Hemorheology and Endothelial Dysfunction</u> , Ophthalmology, Vol. 108, No. 4, 705-710, April 2001.					
EXAMINER				DATE CONSIDERED			
							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/17CP

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam A. PeymanFILING DATE
March 27, 2002

GROUP

(37 CFR 1.98(b))

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.						
	E.M.						
	E.N.						
	E.O.						
	E.P.						
	E.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>A</i>	E.R.	Maguire et al., <u>Laser Treatment in Eyes with Large Drusen</u> , Ophthalmology, Vol. 105, No. 1, 11-23, January 1998.
<i>A</i>	E.S.	Mainster et al., <u>Transpupillary Thermotherapy for Age-Related Macular Degeneration: Long-Pulse Photocoagulation, Apoptosis, and Heat Shock Proteins</u> , Ophthalmic Surgery and Lasers, Vol. 31, No. 5, 359-373, September/October 2000.
<i>A</i>	E.T.	Mullins et al., <u>Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis</u> , Eye, Vol. 15, Part 3, 390-395, June 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/17CP

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam A. Peyman

(Use several sheets if necessary)

FILING DATE
March 27, 2002

GROUP

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						





OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>A</i>	F.R	Mullins et al., <u>Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease</u> , FASEB Journal, Vol. 14, No. 7, 835-846, May 2000.
<i>A</i>	F.S	Peyman et al., <u>Verteporfin Ocular Photodynamic Therapy Combined with Macular Scatter Photocoagulation for Occult or Predominantly Occult Subfoveal Neovascularization in Age-Related Macular Degeneration</u> , Association for Research in Vision and Ophthalmology, Abstract, Tracking No. 02-A-2170, December 7, 2001 (2 pages)
<i>A</i>	F.T	Piguet et al., <u>Evolution of Age-related Macular Degeneration with Choroidal Perfusion Abnormality</u> , American Journal of Ophthalmology, Vol. 113, 657-663, June 1992.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/17CP		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gholam A. Peyman			
				FILING DATE March 27, 2002		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A.						
	G.B.						
	G.C.						
	G.D.						
	G.E.						
	G.F.						
	G.G.						
	G.H.						
	G.I.						
	G.J.						
	G.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L.						
	G.M.						
	G.N.						
	G.O.						
	G.P.						
	G.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	G.R.	Reichel et al., <u>Transpupillary Thermotherapy of Occult Subfoveal Choroidal Neovascularization in Patients with Age-related Macular Degeneration</u> , Ophthalmology, Vol. 106, No. 10, 1908-1914, October 1999.					
	G.S.	Ross et al., <u>Presumed Macular Choroidal Watershed Vascular Filling, Choroidal Neovascularization, and Systemic Vascular Disease in Patients with Age-Related Macular Degeneration</u> , American Journal of Ophthalmology, Vol. 125, No. 1, 71-80, 1998.					
	G.T.	Smith et al., <u>Smoking and Age-Related Maculopathy: The Blue Mountains Eye Study</u> , Archives in Ophthalmology, Vol. 114, 1518-1523, December 1996.					
EXAMINER.				DATE CONSIDERED			
				12/9/03			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PMAN/17CP

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gholam A. Peyman

(Use several sheets if necessary)

FILING DATE
March 27, 2002

GROUP

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>F</i>	H.R	Verteporfin in Photodynamic Study Group, <u>Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions with Occult with no Classic Choroidal Neovascularization - Verteporfin in Photodynamic Therapy</u> , Am. Jour. of Ophthal., May, 2001; 131:541-560
<i>F</i>	H.S	Vingerling et al., <u>Age-related Macular Degeneration is Associated With Atherosclerosis</u> , American Journal of Epidemiology, Vol. 142, No. 4, 404-409, 1995.
<i>FF</i>	H.T	Zhao et al., <u>Delayed macular choriocapillary circulation in age-related macular degeneration</u> , International Ophthalmology, Vol. 19, 1-12, 1995.

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

4. Park
1-25-03
#3/IDS

PATENT

Express Mail No.: EL725699843US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continuation-In-Part of:

Serial No: 10/008,296
Filed: November 13, 2001
Applicant: Peyman
Title: **METHOD TO TREAT AGE-RELATED
MACULAR DEGENERATION**
Art Unit: 3763
Examiner: Not yet assigned
Attorney Docket: PMAN-17CP

Cincinnati, Ohio 45202

March 27, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are enclosed. No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe that any fees are due in connection with this submission. However, if such petition is due or any fees are necessary, the Commissioner may consider this to be a request for such and charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.


Beverly A. Lyman
Reg. No. 41,961

2700 Carew Tower
Cincinnati OH 45202
(513) 241-2324
(513) 421-7269 Facsimile